Laurie Elit and Hal Hirte
Background: Traditional management of women with advanced ovarian cancer with surgery and chemotherapy provides limited duration of survival. Targeting specific pathways in angiogenesis or DNA repair may provide therapeutic benefit.
Results: In this manuscript, we review the use of various compounds including antibodies that target specific growth factors receptors or ligands for receptors as well as small molecule compounds that inhibit tyrosine kinase activities or regulate the DNA repair mechanism in the management of women with ovarian, fallopian tube and primary peritoneal cancers. Randomized clinical trials have shown a PFS benefit in the use of bevacizumab in the adjuvant setting and at disease recurrence. Randomized clinical trials are currently ongoing with several PARP inhibitors in the maintenance setting post-chemotherapy and in the recurrent disease setting.
Conclusion: In particular, bevacizumab an antibody to VEGF-A and the PARP inhibitors show promise in extending overall survival from this disease. Use of these agents especially in a maintenance strategy is promising
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 